Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 11, 2018
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation ...
September 11, 2018
Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018/PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that new ...
September 11, 2018
Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing ...
September 10, 2018
Innate Pharma announces data presentations at upcoming scientific meetings
Marseille, France, September 10, 2018, Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that updated data from ongoing clinical trials evaluating ...
September 10, 2018
Sensorion to Partner with Vestibular Disorders Association (VeDA) in Sponsorship of Balance Awareness Week 2018 for Vestibular Disorders
MONTPELLIER, France, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sensorion(FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that ...
September 10, 2018
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
RALEIGH, N.C., Sept. 10, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a leading commercial stage specialty pharmaceutical company dedicated to patients living with ...
September 10, 2018
Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
SANTA MONICA, Calif., and HEMEL HEMPSTEAD, United Kingdom, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological ...
September 10, 2018
TRACON Pharmaceuticals Announces Publication of Phase 1b Results for TRC105 in Combination with Inlyta® in Patients with Advanced or Metastatic RCC
SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
September 7, 2018
OSE Immunotherapeutics Reports First-Half 2018 Results and Provides a Corporate Update
NANTES, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), today reported its consolidated half-year financial results as of June ...
September 7, 2018
Zealand sells royalty streams and milestones for USD 205 million to Royalty Pharma
Copenhagen, September 6, 2018 - Zealand Pharma A/S ("Zealand") (ZEAL.CO), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today ...
September 7, 2018
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation ...
September 7, 2018
Zealand Pharma to attend J.P. Morgan Cazenove and Morgan Stanley Global Healthcare Conferences
Copenhagen, September 7, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will attend the J.P. Morgan Cazenove Pan-European ...
September 7, 2018
Novus Therapeutics to Postpone Offering of Common Stock
IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), ...
September 6, 2018
Kiadis Pharma announces two senior management appointments
Amsterdam, The Netherlands, September 6, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today ...
September 6, 2018
Sensorion Presents Three Posters At The 55th Inner Ear Biology Workshop
MONTPELLIER, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today presented ...
September 6, 2018
Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
NEW YORK, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization ...
September 6, 2018
Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit
PASADENA, Calif.--(BUSINESS WIRE)-- Data presented from the lowest two dose cohorts (100mg and 200mg ARO-HBV) Up to 4.0 log10 reduction in HBsAg observed following three ...
September 6, 2018
Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients
REDWOOD CITY, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...
September 6, 2018
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
September 6, 2018
Zosano Pharma to Present Phase 3 Safety Study Update for ADAM™ Technology in the Delivery of Zolmitriptan at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference
FREMONT, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver ...
Page 41 of 138